Poop pills and a liquid diet: a new hope for kids with colitis?

NCT ID NCT05679622

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests whether giving children with active ulcerative colitis a series of fecal microbiota transplants (FMT) along with a special liquid diet (partial enteral nutrition) can help control the disease. The trial includes children aged 2 to 16 who either have not responded to standard treatments or are newly diagnosed with mild-to-moderate colitis. The goal is to see if this combination can reduce symptoms and inflammation, and possibly avoid stronger medications or surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fecal microbiota transplantation (FMT) plus partial enteral nutrition (PEN)
What this could lead to
If it works, this could offer a new treatment option for children with ulcerative colitis that does not respond to standard therapies, potentially reducing the need for stronger drugs or surgery.
What could go wrong
This is a small, early-stage study with only 30 participants. FMT carries risks like fever, abdominal pain, or infection, and the long-term effects are unknown. The diet component may be difficult for children to follow.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tongji Hospital

    RECRUITING

    Wuhan, 430030, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.